Adage Capital Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Adage Capital Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,500,000	Closed	-$10.8M	–	974
2025 Q3	$10.8M	Buy	+1,500,000	New	+$78.2M	0.02%	614
2025 Q1	–	Sell	-155,000	Closed	-$8.39M	–	905
2024 Q4	$8.39M	Sell	155,000 -350,000	-69%	-$17.9M	0.01%	647
2024 Q3	$25.5M	Sell	505,000 -1,320,000	-72%	-$61.9M	0.05%	392
2024 Q2	$80.2M	Sell	1,825,000 -459,913	-20%	-$19.5M	0.15%	145
2024 Q1	$115M	Buy	2,284,913 +759,196	+50%	+$41.2M	0.22%	95
2023 Q4	$92.1M	Sell	1,525,717 -426,986	-22%	-$22M	0.19%	120
2023 Q3	$111M	Buy	1,952,703 +580,375	+42%	+$32M	0.25%	86
2023 Q2	$70M	Sell	1,372,328 -296,543	-18%	-$7.98M	0.15%	154
2023 Q1	$35.7M	Buy	+1,668,871	New	+$28.1M	0.08%	287
2022 Q1	–	Sell	-1,011,589	Closed	-$10M	–	1112
2021 Q4	$10M	Hold	1,011,589	–	–	0.02%	696
2021 Q3	$10.1M	Hold	1,011,589	–	–	0.02%	680
2021 Q2	$10.5M	Hold	1,011,589	–	–	0.02%	676
2021 Q1	$10.3M	Hold	1,011,589	–	–	0.02%	664
2020 Q4	$11.5M	Buy	+1,011,589	New	+$10.7M	0.03%	557

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners's MLTX Position: Q4 2025 in Review

Adage Capital Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 1,500,000 shares — an estimated $10.8M sold.

Adage Capital Partners first reported a position in MLTX in Q4 2020 and held it in 14 quarters. The position peaked at $115M in Q1 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Adage Capital Partners reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Adage Capital Partners sold 1,500,000 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $10.8M.
Adage Capital Partners first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 14 quarters.
Adage Capital Partners's MoonLake Immunotherapeutics position peaked at $115M in Q1 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.